Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

November 5, 2025

Dana-Farber

Objective:

To discuss the prognostic value of MAdCAM-1 in metastatic renal cell carcinoma.

Approach:

Key Findings:

Circulating MAdCAM-1 levels are prognostic of clinical outcomes in metastatic renal cell carcinoma.
MAdCAM-1 serves as a dynamic biomarker for tracking gut dysbiosis-driven immune dysregulation.
The MAdCAM-1 pathway could be a therapeutic target for microbiota-directed interventions.

Interpretation:

MAdCAM-1 levels can provide insights into patient prognosis and potential treatment strategies.

Limitations:

Further research is needed to validate findings across diverse populations.
The role of gut microbiota in immune regulation requires more exploration.

Conclusion:

MAdCAM-1 has potential as a biomarker and therapeutic target in treatment-resistant renal cell carcinoma.

Marc Machaalani, MD on MAdCAM-1

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Marc Machaalani, MD on MAdCAM-1

Related Content

Endogenous Competition of circ_001024 for miR-145-3p: Implications for GLUT5 Regulation in Renal Cell Carcinoma

Dana-Farber Research News 07.01.2026

2026 AACR Renal Cell Carcinoma Highlights